1-乙基-3-(2-甲基丙基)-1H-吡唑-5-羧酸 | 1015845-75-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-乙基-3-(2-甲基丙基)-1H-吡唑-5-羧酸
• 中文别名: 1-乙基-3-异丁基-1H-吡唑-5-羧酸
• 英文名称: 1-Ethyl-3-(2-methylpropyl)-1H-pyrazole-5-carboxylic acid
• 英文别名: 1-Ethyl-3-isobutyl-5-pyrazolecarboxylic acid；2-ethyl-5-(2-methylpropyl)pyrazole-3-carboxylic acid
• CAS: 1015845-75-6
• 化学式: C₁₀H₁₆N₂O₂
• mdl: MFCD08059761
• 分子量: 196.249
• InChiKey: DZGHINKQRGJIHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  、 1-乙基-3-(2-甲基丙基)-1H-吡唑-5-羧酸 在 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  Identification of non-peptidic cysteine reactive fragments as inhibitors of cysteine protease rhodesain

  摘要：

  Rhodesain, the major cathepsin L-like cysteine protease in the protozoan Trypanosoma brucei rhodesiense, the causative agent of African sleeping sickness, is a well-validated drug target. In this work, we used a fragment-based approach to identify inhibitors of this cysteine protease, and identified inhibitors of T. brucei. To discover inhibitors active against rhodesain and T. brucei, we screened a library of covalent fragments against rhodesain and conducted preliminary SAR studies. We envision that in vitro enzymatic assays will further expand the use of the covalent tethering method, a simple fragment-based drug discovery technique to discover covalent drug leads. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.08.074

文献信息

• BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES
  申请人：Baldwin Ian Robert

  公开号：US20110178063A1

  公开（公告）日：2011-07-21

  The invention is directed to certain novel compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.

  该发明涉及公式（I）的某些新化合物及其盐。该发明的化合物是PI3-激酶活性的抑制剂。
• US8658635B2
  申请人：——

  公开号：US8658635B2

  公开（公告）日：2014-02-25
• [EN] SORTILIN INHIBITORS<br/>[FR] INHIBITEURS DE LA SORTILINE
  申请人：[en]SORTINA PHARMA AB

  公开号：WO2023101595A1

  公开（公告）日：2023-06-08

  The present invention is directed towards compounds of formula (I), capable of binding to sortilin and thereby useful as sortilin inhibitors in the treatment of diseases, disorders and conditions associated with sortilin activity and binding of ligands, such as progranulin, to sortilin.